Monday, January 18, 2021
Home Latest Pharma-News New Novartis medicine Adakveo® (crizanlizumab) approved by FDA for the treatment of...

New Novartis medicine Adakveo® (crizanlizumab) approved by FDA for the treatment of individuals living with sickle cell disease

Nov 15, 2019: FDA approved Novartis’s Adakveo (crizanlizumab-tmca) for the treatment to reduce the frequency of vaso-occlusive crisis in sickle cell disease for patients age 16 years and older. it is first targeted therapy of its kind. It inhibits selectin protein that contributes cell sticking and results in a vaso-occlusive crisis. The FDA granted Priority Review, Orphan Drug designation and Breakthrough Therapy designation for Adakveo. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-crizanlizumab-tmca-sickle-cell-disease

- Advertisement -

LEAVE A REPLY

Please enter your comment!
Please enter your name here

7 − six =

Most Popular

GSK presents positive efficacy data of dostarlimab at ASCO Gastrointestinal Cancers Symposium

January 16, 2021: "GlaxoSmithKline (GSK) plc announced updated data from GARNET cohort F evaluating dostarlimab in mismatch repair-deficient (dMMR) non-endometrial advanced solid...

Bharat Biotech signs agreement with Precisa Medicamentos for supply of ‘COVAXIN™’ to Brazil

January 12, 2020: "Bharat Biotech announced that it has signed an agreement with Precisa Medicamentos for the supplies of COVAXIN™ to Brazil.

What Is a Blockbuster Drug?

What Is a Blockbuster Drug? "Blockbuster drugs are those that generate at least $1 billion of revenue per...

Boehringer Ingelheim and Enara Bio join forces to discover Cancer Immunotherapies

January 12th, 2021: Boehringer Ingelheim and Enara Bio announced that they have entered into a strategic collaboration and licensing agreement to research...